# Sofetabart Mipitecan

Source: https://onco.cc/drugs/sofetabart-mipitecan/  
OnCo record `sofetabart-mipitecan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.

## Summary

Sofetabart Mipitecan (LY4170156) is an antibody-drug conjugate developed by Eli Lilly and. Its target is Folate receptor alpha (the sponsor names folate receptor alpha). The sponsor states: An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer), in ovarian cancer. The largest, NCT07213804, plans to enrol 1630 participants with primary completion expected 2028-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Sofe-M
- Tags: pipeline; ctgov-ingest
- Code: LY4170156
- Modality: ADC
- Mechanism: An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells.

## Sources

- ClinicalTrials.gov: trials of Sofetabart Mipitecan: https://clinicaltrials.gov/search?intr=LY4170156

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- trials: [A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer](https://onco.cc/trials/nct07213804/)

---
JSON: https://onco.cc/api/v1/entities/sofetabart-mipitecan.json